Trading

Data

Solutions

Insights

Orig3n Stock

orig3n.comHealthcareFounded: 2014Funding to Date: $85.64MM

Orig3n is a developer of DNA tests designed to help people understand the links between their genes and how their minds and bodies work, and researcher of cellular science to develop personalized therapies for repairing tissue damage and disease.

Buy or sell Orig3n stock Learn more about Orig3n IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

View Enterprise Value for Orig3n.

Register Today

Team

Management Team

Robin Smith

Co-Founder & Chief Executive Officer

Marcie Glicksman Ph.D

Chief Scientific Officer

Kate Blanchard

Co-Founder & Chief Operating Officer

Michael Fang MD

Chief Medical Officer

Board Members

Justin Xiang Ph.D

Syno Capital

Byron Smith

Mountain Group Partners

Angela Ruggiero

Other companies like Orig3n in the Healthcare sector

Neuralink

Sector

Healthcare

Last Round Est. Valuation

$2.15B

Altos Labs

Sector

Healthcare

Last Round Est. Valuation

$3.67B

Sector

Sector

Last Round Est. Valuation

$1.08B

Synchron

Sector

Healthcare

Last Round Est. Valuation

$400.53MM

Headspace

Sector

Healthcare

Last Round Est. Valuation

$298.33MM

Grail

Sector

Healthcare

Last Round Est. Valuation

$4.26B

OURA

Sector

Healthcare

Allurion Technologies

Sector

Healthcare

News

Boston Globe 09/08/2020

State suspends COVID-19 testing at Orig3n, Boston lab responsible for at least 383 false positive results - The Boston Globe

A state investigation found the lab “put patients at immediate risk of harm.”

Popular Topics

Popular Topics

Orig3n Stock

Register for Details